Flinn, I. W., O’Brien, S., Kahl, B., Patel, M., Oki, Y., Foss, F. F., . . . Horwitz, S. (2018). Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood.
Styl ChicagoFlinn, Ian W., et al. "Duvelisib, a Novel Oral Dual Inhibitor of PI3K-δ,γ, Is Clinically Active in Advanced Hematologic Malignancies." Blood 2018.
Citace podle MLAFlinn, Ian W., et al. "Duvelisib, a Novel Oral Dual Inhibitor of PI3K-δ,γ, Is Clinically Active in Advanced Hematologic Malignancies." Blood 2018.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..